Phase IV Post-Marketing Surveillance Study to Measure the Efficacy and Safety of Dr.Ortho Pain Relief Oil in Subjects Suffering from Acute Sports Injury, Knee Pain, Stiffness in Joints, Lower Back Pain, Neck Rigidity, Backache and Inflammation in Joints

A Single Centric, Open-Label, Non-Randomized Phase IV Post-Marketing Surveillance Study to Measure the Efficacy and Safety of Dr.Ortho Pain Relief Oil in Subjects Suffering from Acute Sports Injury, Knee Pain, Stiffness in Joints, Lower Back Pain, Neck Rigidity, Backache and Inflammation in Joints

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/07/034542

Enrollment

120

Registered

2021-07-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M959- Acquired deformity of musculoskeletal system, unspecified

Interventions

Intervention1: Dr. Ortho Oil: 5 to 10 ml of topical application of Dr. Ortho oil and gently massage the affected area twice a day Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age Between 18 - 80 Years 2. Subjects suffering from Knee pain and joint pain and arthritis 3. Willingness to Take part in Study and able to attend all Scheduled Visits 4. Subjects suffering from Acute sports injury, strains, sprain, chronic Arthritis, back pain, knee pain, and other joint pain

Exclusion criteria

Exclusion criteria: 1. Pregnant, Breastfeeding, subjects undergone any surgery and else take taken part in any clinical Trial 2. Not willing to Sign the ICF or give the consent

Design outcomes

Primary

Measure	Time frame
1. To assess the percentage of subjects with significant symptomatic reduction of joint muscle stiffness, neck rigidity, and backache assessed through Investigator Assessment Scale and Subject Assessment QuestionnairesTimepoint: Day 1 to day 30	—

Secondary

Measure	Time frame
1.Improvement in the VAS scoring on the successive application as compared to baseline 2.Incidence of any AEs during the studyTimepoint: Day 1 to day 30	—

Countries

India

Contacts

Public ContactMr Hasan Ali Ahmed

Divisa Herbal Care

vijaykimtata.vk@gmail.com9816333352

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026